Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Molecular Symphony of Mitophagy: Ubiquitin-Specific Protease-30 as a Maestro for Precision Management of Neurodegenerative Diseases

A. Siwach, H. Patel, A. Khairnar, P. Parekh

. 2025 ; 31 (1) : e70192. [pub] -

Language English Country England, Great Britain

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc25010384

Grant support
LX22NPO5107 (MEYS) European Union: NextGenerationEU
National Institute of Pharmaceutical Education and Research (NIPER) seed fund-Ahmedabad, Department of Pharmaceutics, Ministry of Chemicals and Fertilizers, Government of India
BT/RLF/Re-entry/24/2017 Ramalingaswami fellowship, Department of Biotechnology

INTRODUCTION: Mitochondrial dysfunction stands as a pivotal feature in neurodegenerative disorders, spurring the quest for targeted therapeutic interventions. This review examines Ubiquitin-Specific Protease 30 (USP30) as a master regulator of mitophagy with therapeutic promise in Alzheimer's disease (AD) and Parkinson's disease (PD). USP30's orchestration of mitophagy pathways, encompassing PINK1-dependent and PINK1-independent mechanisms, forms the crux of this exploration. METHOD: A systematic literature search was conducted in PubMed, Scopus, and Web of Science, selecting studies that investigated USP's function, inhibitor design, or therapeutic efficacy in AD and PD. Inclusion criteria encompassed mechanistic and preclinical/clinical data, while irrelevant or duplicate references were excluded. Extracted findings were synthesized narratively. RESULTS: USP30 modulates interactions with translocase of outer mitochondrial membrane (TOM) 20, mitochondrial E3 ubiquitin protein ligase 1 (MUL1), and Parkin, thus harmonizing mitochondrial quality control. Emerging novel USP30 inhibitors, racemic phenylalanine derivatives, N-cyano pyrrolidine, and notably, benzosulphonamide class compounds, restore mitophagy, and reduce neurodegenerative phenotypes across diverse models with minimal off-target effects. Modulation of other USPs also influences neurodegenerative disease pathways, offering additional therapeutic avenues. CONCLUSIONS: In highlighting the nuanced regulation of mitophagy by USP30, this work heralds a shift toward more precise and effective treatments, paving the way for a new era in the clinical management of neurodegenerative disorders.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010384
003      
CZ-PrNML
005      
20250429135153.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/cns.70192 $2 doi
035    __
$a (PubMed)39840724
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Siwach, Ankit $u Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat, India $u School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan, India
245    10
$a Molecular Symphony of Mitophagy: Ubiquitin-Specific Protease-30 as a Maestro for Precision Management of Neurodegenerative Diseases / $c A. Siwach, H. Patel, A. Khairnar, P. Parekh
520    9_
$a INTRODUCTION: Mitochondrial dysfunction stands as a pivotal feature in neurodegenerative disorders, spurring the quest for targeted therapeutic interventions. This review examines Ubiquitin-Specific Protease 30 (USP30) as a master regulator of mitophagy with therapeutic promise in Alzheimer's disease (AD) and Parkinson's disease (PD). USP30's orchestration of mitophagy pathways, encompassing PINK1-dependent and PINK1-independent mechanisms, forms the crux of this exploration. METHOD: A systematic literature search was conducted in PubMed, Scopus, and Web of Science, selecting studies that investigated USP's function, inhibitor design, or therapeutic efficacy in AD and PD. Inclusion criteria encompassed mechanistic and preclinical/clinical data, while irrelevant or duplicate references were excluded. Extracted findings were synthesized narratively. RESULTS: USP30 modulates interactions with translocase of outer mitochondrial membrane (TOM) 20, mitochondrial E3 ubiquitin protein ligase 1 (MUL1), and Parkin, thus harmonizing mitochondrial quality control. Emerging novel USP30 inhibitors, racemic phenylalanine derivatives, N-cyano pyrrolidine, and notably, benzosulphonamide class compounds, restore mitophagy, and reduce neurodegenerative phenotypes across diverse models with minimal off-target effects. Modulation of other USPs also influences neurodegenerative disease pathways, offering additional therapeutic avenues. CONCLUSIONS: In highlighting the nuanced regulation of mitophagy by USP30, this work heralds a shift toward more precise and effective treatments, paving the way for a new era in the clinical management of neurodegenerative disorders.
650    _2
$a lidé $7 D006801
650    12
$a mitofagie $x fyziologie $x účinky léků $7 D063306
650    12
$a neurodegenerativní nemoci $x farmakoterapie $x metabolismus $7 D019636
650    _2
$a zvířata $7 D000818
650    _2
$a specifické proteázy ubikvitinu $x metabolismus $x antagonisté a inhibitory $7 D064570
650    _2
$a individualizovaná medicína $x metody $7 D057285
650    _2
$a thiolesterhydrolasy $x metabolismus $7 D013869
650    _2
$a mitochondriální proteiny $7 D024101
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Patel, Harit $u Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat, India
700    1_
$a Khairnar, Amit $u Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat, India $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u International Clinical Research Center (ICRC), St. Anne's University Hospital, Brno, Czech Republic $u International Clinical Research Center (ICRC), Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Parekh, Pathik $u Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, USA $1 https://orcid.org/000000024385751X
773    0_
$w MED00173405 $t CNS neuroscience & therapeutics $x 1755-5949 $g Roč. 31, č. 1 (2025), s. e70192
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39840724 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135148 $b ABA008
999    __
$a ok $b bmc $g 2311628 $s 1247465
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 31 $c 1 $d e70192 $e - $i 1755-5949 $m CNS neuroscience & therapeutics $n CNS Neurosci Ther $x MED00173405
GRA    __
$a LX22NPO5107 (MEYS) $p European Union: NextGenerationEU
GRA    __
$p National Institute of Pharmaceutical Education and Research (NIPER) seed fund-Ahmedabad, Department of Pharmaceutics, Ministry of Chemicals and Fertilizers, Government of India
GRA    __
$a BT/RLF/Re-entry/24/2017 $p Ramalingaswami fellowship, Department of Biotechnology
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options